Russell Hirsch, M.D., Ph.D. is a Managing Director of Prospect Venture Partners. Russell co-founded Prospect Venture Partners II and III, as dedicated life science funds with over $1 billion in capital under management. Prior to establishing Prospect Venture Partners II and III, Russell was a member of the Health Care Technology Group at Mayfield. He joined Mayfield in 1992, served as a Venture Partner from 1993 to 1994 and as a General Partner from 1995-2000. Russell played a key role in Mayfield's investment activities in the biotechnology and medical device sectors. As an Associate, he participated actively in the incubation of Millennium Pharmaceuticals (acquired by Takeda) and as a General Partner he was responsible for the incubation of Intuitive Surgical Devices (NASDAQ:ISRG).
Prior to Mayfield, Russell was at the University of California San Francisco from 1984-1992 where he was engaged in biomedical research. His work, published in a variety of respected journals, focused on important aspects of hepatitis B viral replication. His descriptions of the reverse transcription and packaging functions of polymerase gene products merited publication in Nature.